Monday, November 7, 2016
High Incidence of Chikungunya Virus and Frequency of Viremic Blood Donations during Epidemic Puerto Rico USA 2014 Volume 22 Number 7—July 2016 Emerging Infectious Disease journal CDC
High Incidence of Chikungunya Virus and Frequency of Viremic Blood Donations during Epidemic Puerto Rico USA 2014 Volume 22 Number 7—July 2016 Emerging Infectious Disease journal CDC
High Incidence of Chikungunya Virus and Frequency of Viremic Blood Donations during Epidemic, Puerto Rico, USA, 2014 - Volume 22, Number 7July 2016 - Emerging Infectious Disease journal - CDC
Volume 22, Number 7July 2016
Research
High Incidence of Chikungunya Virus and Frequency of Viremic Blood Donations during Epidemic, Puerto Rico, USA, 2014
On This Page
- Materials and Methods
- Results
- Discussion
- Suggested Citation
Figures
- Figure 1
- Figure 2
- Figure 3
Tables
- Table 1
- Table 2
- Table 3
Downloads
- PDF[718 KB - 8 pgs]
- RIS[TXT - 2 KB]
Graham Simmons
, Vanessa Brès, Kai Lu, Nathan M. Liss, Donald J. Brambilla, Kyle R. Ryff, Roberta Bruhn, Edwin Velez, Derrek Ocampo, Jeffrey M. Linnen, Gerardo Latoni, Lyle R. Petersen, Phillip C. Williamson, and Michael P. Busch
Author affiliations: Blood Systems Research Institute, San Francisco, California, USA (G. Simmons, K. Lu, N.M. Liss, R. Bruhn, M.P. Busch); University of California, San Francisco (G. Simmons, M.P. Busch); Hologic, Inc., San Diego, California, USA (V. Brès, D. Ocampo, J.M. Linnen); RTI International, Rockville, Maryland, USA (D.J. Brambilla); Puerto Rico Department of Health, San Juan, Puerto Rico, USA (K.R. Ryff); Banco de Sangre de Servicios Mutuos, San Juan, Puerto Rico, USA (E. Velez, G. Latoni); Centers for Disease Control and Prevention, Fort Collins, Colorado, USA (L.R. Petersen); Creative Testing Solutions, Tempe, Arizona, USA (P.C. Williamson)
Suggested citation for this article
Abstract
Chikungunya virus (CHIKV) caused large epidemics throughout the Caribbean in 2014. We conducted nucleic acid amplification testing (NAAT) for CHIKV RNA (n = 29,695) and serologic testing for IgG against CHIKV (n = 1,232) in archived blood donor samples collected during and after an epidemic in Puerto Rico in 2014. NAAT yields peaked in October with 2.1% of donations positive for CHIKV RNA. A total of 14% of NAAT-reactive donations posed a high risk for virus transmission by transfusion because of high virus RNA copy numbers (104109 RNA copies/mL) and a lack of specific IgM and IgG responses. Testing of minipools of 16 donations would not have detected 62.5% of RNA-positive donations detectable by individual donor testing, including individual donations without IgM and IgG. Serosurveys before and after the epidemic demonstrated that nearly 25% of blood donors in Puerto Rico acquired CHIKV infections and seroconverted during the epidemic.
Chikungunya virus (CHIKV), a mosquitoborne, positive-sense RNA virus of the family Togaviridae, causes an acute febrile illness and severe polyarthralgia that can persist for months or years in some patients (13). Serious outcomes and deaths are rarely observed. However, newborns and other vulnerable populations are at risk for severe complications (4).
In late 2013, cases of CHIKV infection were reported in the French Collectivity of Saint Martin, which is part of the French Antilles (5), constituting the first instance of autochthonous transmissions of CHIKV in the Americas in the past century (6). In an immunologically naive population, CHIKV spread rapidly throughout the Caribbean region and beyond to most countries in the Western Hemisphere (7), including 11 autochthonous cases reported in Florida, USA, in September 2014 (8).
CHIKV has yet to be demonstrated to be transmissible by blood transfusion (9). However, this finding might result from difficulties in discriminating transfusion transmission from locally acquired mosquitoborne infection. Transfusion transmission is probable, given previous instances of laboratory-acquired infections and infection of healthcare workers by blood exposures (10). Asymptomatically infected persons can have viral loads >105 PFU/mL (11,12) and are a substantial risk for transfusion transmission.
Estimates of asymptomatic CHIKV infection vary widely. A recent study in Puerto Rico (13) confirmed previous estimates that 10%25% of total infections are subclinical (1416). However, other studies with the Asian genotype suggest that a greater proportion of cases might be asymptomatic or have only mild and transient symptoms (17,18). CHIKV infection can result in viral loads >108 PFU/mL (19). Thus, relatively high viral loads likely present in some presymptomatic donors might be a threat for transfusion transmission. Recently, a case of transfusion transmission of the related alphavirus Ross River virus, has been reported (20), stemming from transfusion of the erythrocyte component from a blood donor who reported symptoms of Ross River virus infection 2 days after donating blood.
To mitigate the theoretical risk for transmission, some blood collection organizations in regions with large CHIKV epidemics have suspended local blood collection, implemented nucleic acid amplification testing (NAAT) of erythrocyte and plasma donations for CHIKV RNA, and introduced pathogen-reduction technology for platelet components (21,22). To directly assess the threat that CHIKV poses to the blood supply, and given the absence of licensed NAAT for donor screening, we conducted NAAT surveys of blood donors in Puerto Rico during the 2014 epidemic and complementary serosurveys before and after the epidemic.
Materials and Methods
Human Subjects Research Approval
We performed retrospective testing of anonymous blood donor samples and minipools. The study was approved by the University of California, San Francisco Committee for Human Research.
Specimens
Creative Testing Solutions (Tempe, AZ, USA) retained, aliquoted, and archived at ?70°C residual plasma from EDTA-anticoagulated blood collected in Puerto Rico and supplied for routine blood donor screening during the second half of 2014 and for a brief period during March 2015. Current molecular testing procedures at Creative Testing Solutions require that plasma samples be pooled into a minipool of 16 donor samples. Minipools prepared from blood donations in Puerto Rico were frozen during June 20December 31, 2014. The sample set consisted of 1,667 minipools representing 26,672 individual donation samples from donors in Puerto Rico. Minipools were irreversibly stripped of their original labels and given a unique bar code that was linked only to month of collection.
In addition, 3,007 individual donor samples (IDS) were collected during the epidemic (SeptemberNovember 2014), and ?1,000 samples were saved per month. IDS were irreversibly stripped of all identifying information and given a unique bar code. Only basic demographic data (donors age, race, sex, county of residence, and week of collection) were retained in a secure database. Anonymous minipools and individual donor samples were retained, aliquoted, frozen, and stored at ?70°C.
Finally, we retained 1,031 individual donation samples obtained during March 19, 2015, for a postepidemic serosurvey. Demographic data, including the donors age, sex, and zip code of residence, but not individual donor identifiers, were retained for these samples to enable analysis of serologic test results by using demographic strata.
Viral RNA Testing
We performed viral RNA testing by using a prototype real-time CHIKV/dengue virus (DENV) target-capture, transcription-mediated amplification (TC-TMA) assay (12) (Hologic, Inc., San Diego, CA, USA). Plasma samples (0.5 mL) were tested by using the fully automated Panther System (Hologic, Inc.), which performs target capture, amplification, and real-time detection in the presence of an internal control. We achieved detection by using single-stranded, fluorescent-labeled nucleic acid probes that were present during amplification of the target. The time for the fluorescent signal to reach a specified threshold was proportional to the starting CHIKV and DENV RNA concentrations. Target capture oligonucleotides, TMA primers, and detection probes hybridize with highly conserved regions of CHIKV or DENV RNA genomes and were designed to detect all 3 major CHIKV lineages and all 4 DENV types. We set the cutoff value for reactive specimens at 1,000 relative fluorescent units.
Estimated viral loads for CHIKV were calculated relative to the emergence time of the emitted fluorescence of a calibration curve generated by testing logarithmic dilutions of a CHIKV in vitrosynthesized transcript. ID-NAATreactive specimens were diluted 1:16 in defribrinated, delipidated, pooled plasma (SeraCare, Gaithersburg, MD, USA) to mimic minipool testing and tested by TC-TMA assay to assess whether donation samples detected by ID-NAAT would have been detectable by minipool NAAT (MP-NAAT).
We determined limits of detection (LODs) by using an in vitro transcript corresponding to each analyte and calculation by using Enterprise Guide 5.1 Probit analysis and the Normal model (SAS Institute, Cary, NC, USA). For DENV-14, the 50% LOD was 1.72.1 copies/mL, and the 95% LOD was 7.113.0 copies/mL in the IDS format. For CHIKV, the 50% LOD was 4.6 copies/mL, and the 95% LOD was 19.7 copies/mL in the IDS format. In 16-member minipools for DENV-14, the 50% LOD was from 27.233.6 copies/mL, and the 95% LOD was 116.8208.0 copies/mL. For CHIKV, the 50% LOD was 73.6 copies/mL, and the 95% LOD was 315.2 copies/mL in the MP format.
Serologic Analysis
Plasma samples were tested for CHIKV IgM or IgG by using 2 ELISAs (Euroimmun US, LLC, Morris Plains, NJ, USA). These CHIKV ELISAs had specificities of 82% and 95% and sensitivities of 85% and 88% for IgM and IgG, respectively, when compared with those for 2 established in-house assays (23). Samples were diluted 1:100 and tested in duplicate according to the manufacturers instructions. Sample-to-calibrator ratios were calculated. In validating the assay, we found that preepidemic samples (n = 201) yielded no strongly positive samples when the manufacturers cutoff value >1.1 sample-to-calibrator ratio was used. However, 5 samples showed borderline reactivity (sample-to-calibrator ratios 1.131.37).
These 5 samples did not show positive results by reflex IgM testing, plaque-reduction neutralization testing (PRNT), or Western blot analysis when cell culturepropagated virus (strain 99659) was used as antigen. Testing of randomly chosen highly and moderately IgG-reactive samples from March 2015 by PRNT showed strong neutralization in all instances. Thus, the assay does not appear to yield strongly reactive false-positive results, but might yield a small frequency (5/201, 2.5%) of low-level reactive false-positive results. Therefore, a new cutoff value was established by using mean sample-to-calibrator ratios of preepidemic samples plus 5 SDs (1.42). Testing of multiple IgG-negative samples from both sample sets by IgM ELISA (20 samples), PRNT (20 samples), and Western blot analysis (10 samples) did not yield any suspected false-negative results, which suggested that false-negative results were also not common.
Estimation of Detection Periods for MP-NAAT and IDS-NAAT
On the basis of the estimate for incidence of infection during the 2014 epidemic derived from serosurveys and MP-NAATpositive results for the study period, we derived an estimate for duration of viremia detectable by the CHIKV TMA NAAT applied to minipools by using the approach of Busch et al. (24). We estimated the number of NAAT-positive donations in each minipool from minipool-testing results by using a program developed at the Centers for Disease Control and Prevention (Atlanta, GA, USA) (25). If Ti is the proportion of NAAT-positive donations in month i and P is seroprevalence of CHIKV at the end of the epidemic, then the TMA detection interval of CHIKV virus RNA (W) is estimated as
Confidence limits for W were estimated by using a delta method estimate of the variance of W. Estimates for length of the individual donor sample-positive detection periods preceding and following the MP-NAATdetectable period were derived from results of screening 3,007 individual donor samples by using ratios of samples detectable only by ID-NAAT that lacked IgG or contained IgG relative to the number of samples detectable at a dilution of 1:16. Confidence limits for these detection periods were derived by bootstrapping the assay results ratios (2/21) and (33/21) to obtain their variances, and then combining those with the variance associated with the estimate for the minipool detection period to obtain the variance of each of the 2 window estimates.
Results
Of 1,668 minipools tested, 1 was positive for DENV RNA, and 161 (9.7%) were positive for CHIKV RNA (Table 1). This finding indicates a minimum MP-NAATdetectable infection rate of 0.6% (161 positive donations of 26,688 total donations), assuming only 1 of the 16 donations in each positive minipool was viremic. However, because the reactive minipool proportion peaked at 19.5% in September 2014 (Table 1), some pools would probably contain >1 viremic donation.
Figure 1. Estimated percentage of blood donations positive for chikungunya virus (CHIKV) RNA during a chikungunya epidemic, Puerto Rico, USA, 2014. CHIKV RNA-positive minipools of 16 donors were used to estimate the percentage...
Individual donations comprising reactive minipools were not archived for further testing. Thus, we could not directly determine numbers of reactive IDS per reactive minipool. Therefore, we used a published algorithm (25) to estimate the proportion of donations that would contain CHIKV RNA at levels detectable by MP-NAAT (Table 1). This modification yielded an estimate for MP-NAAT detectable viremia of 0.65% for the overall season and an upper limit of 0.93%. The highest estimated proportion of MP-NAATdetectable CHIKV RNA-positive donations was during September and October (1.34% and 1.31% of donations reactive for CHIKV RNA by MP-NAAT, respectively) (Table 1). This estimation represented a slightly delayed peak when compared with suspected and confirmed clinical cases reported in Puerto Rico (Figure 1).
Figure 2. Viral loads for chikungunya virus (CHIKV) in blood donations during a chikungunya epidemic, Puerto Rico, USA, 2014. A) Positive minipool (MP) viral loads. Estimated viral loads (RNA copies/mL) were calculated for...
Although not optimized to be quantitative, the TC-TMA assay provided approximate viral RNA copy numbers (Figure 2, panel A). Several minipools, particularly from early in the epidemic, had >107 copies/mL, although they were tested as a minipool, and thus effectively diluted 1:16. Of 161 reactive minipools, 125 had quantifiable viral loads. Remaining minipools had viral loads less than an estimated value of 0.5 log copies/mL (according to the calibration curve). The median viral load of 161 reactive minipools was 550 copies/mL (range <3.16 copies/mL2.3 × 107 copies/mL). Donations from November and December had lower viral loads than donations from preceding months.
We also performed testing of archived IDS for CHIKV RNA for 3,007 donations collected in Puerto Rico during SeptemberNovember 2014. We identified 56 confirmed positive donations, and ID-NAAT yields were 1.7%2.1% for the 3 months tested (Table 2). When samples were diluted 1:16 to mimic minipools, proportions of RNA-positive samples detectable by MP-NAAT for SeptemberNovember decreased to 0.4%0.9%. Only 21 (37.5%) of 56 ID-NAATreactive specimens were reactive when tested for CHIKV RNA at a dilution of 1:16. Thus, 35 (62.5%) of 56 specimens would probably have been missed by routine MP-NAAT (Table 2). As expected, viral loads were low in donations reactive only by ID-NAAT. Only 8 of the ID-NAAT onlyreactive samples had quantifiable viral loads (range 5.2760 copies/mL) (Figure 2, panel B).
We performed assays to detect IgM and IgG in the 56 ID-NAATreactive specimens to characterize the relationship between development of IgG and IgM, viral load, and the ability of minipool testing to detect viremic donations (Table 2). Thirteen (23.2%) of 56 samples were seronegative; 2 were detectable only by ID-NAAT. These 2 samples are presumed to represent donors detected in the earliest stages of acute infection. The remaining 11 seronegative viremic donations had detectable viral loads (range 5 ×1021.3 × 108 copies/mL) (Figure 2, panel B), including 8 (14.3%) of 56 with viral loads >104 copies/mL. These samples were probably from donors who were near the peak of viremia, but still collected before seroconversion occurred.
Most CHIKV RNA-reactive samples were IgM positive (75%) and IgG positive (64%); 1 sample was IgM negative and IgG positive. Development of IgG titers is an inverse correlate of CHIKV RNA detection (28); of the IgG-reactive samples, only 4 (11.1%) of 36 were detectable by the less sensitive MP-NAAT. Viral loads of samples sorted on the basis of NAAT results (ID only vs MP-NAAT detectable) and serologic data demonstrate a typical profile of acute viral infection (Figure 2, panel B). The 43 viremic IgM-positive or IgG-positive donations had significantly lower viral loads (median <3.16 copies/mL) than 13 viremic seronegative donations (60,000 copies/mL; p<0.0001 by 2-tailed Mann-Whitney test). Although similar proportions of ID-NAATpositive samples were detected in November (1.7%) and September (1.8%), only 2 (11.8%) of 17 were seronegative in November compared with 6 (33.3%) of 18 in September, which suggested waning of the epidemic and a higher proportion of donations at the end of acute infection.
To estimate the incidence of CHIKV infection during the 2014 epidemic, we performed IgG serologic studies on blood donor specimens collected at the beginning of the epidemic (June 2014; preepidemic) and after the epidemic had subsided (March 2015; postepidemic). Collection was delayed until March to maximize detection of IgG seroconversion and to enable the maximum period for potential donors to recover from symptomatic infection, which would result in self-deferral, or deferral by the blood collection organization.